Search Result

Results for "

hypoglycemic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Apoptosis (3) Autophagy (4) Bacterial (2) COX (1) Cytochrome P450 (1) Dipeptidyl Peptidase (1) Drug Metabolite (1) Endogenous Metabolite (3) Fungal (2) GCGR (3) Glucosidase (8) HBV (2) HIV (1) Influenza Virus (1) Insulin Receptor (2) Integrin (1) Isotope-Labeled Compounds (1) PEPCK (1) Phosphatase (4) Potassium Channel (3) PPAR (1) ROS Kinase (1) TRP Channel (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (5) Endocrinology (3) Infection (7) Inflammation/Immunology (11) Metabolic Disease (34) Neurological Disease (4)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas

HY-N7910

Stachyose

Endogenous Metabolite Metabolic Disease

Stachyose, a kind of oligosaccharides, act as a hypoglycemic agent.
HY-Y0004

2-Pyridinemethanol

Others Metabolic Disease

2-Pyridinemethanol is a pyridylalcohol, with hypoglycemic activity.
HY-15383

Glyparamide

Others Others

Glyparamide is an orally active chlorophenyl-containing sulfonylurea. Glyparamide shows hypoglycemic activity and rarely causes hepatic injury.

Stachyose	Endogenous Metabolite	Metabolic Disease
Stachyose, a kind of oligosaccharides, act as a hypoglycemic agent.

2-Pyridinemethanol	Others	Metabolic Disease
2-Pyridinemethanol is a pyridylalcohol, with hypoglycemic activity.

Glyparamide	Others	Others
Glyparamide is an orally active chlorophenyl-containing sulfonylurea. Glyparamide shows hypoglycemic activity and rarely causes hepatic injury.

HY-130003

Hypoglycemic agent 1	Others	Metabolic Disease
Hypoglycemic agent 1 acts as a therapeutic and/or prophylactic agent for diabetes. Hypoglycemic agent 1 has an action for lowering blood sugar.

HY-135670B

Glycosidase-IN-2

Others Metabolic Disease

Glycosidase-IN-2 (Compound 20) is an azasugar class of glycosidase inhibitor. Glycosidase-IN-2 has hypoglycemic activity.

Glycosidase-IN-2	Others	Metabolic Disease
Glycosidase-IN-2 (Compound 20) is an azasugar class of glycosidase inhibitor. Glycosidase-IN-2 has hypoglycemic activity.

HY-135670A

β-glycosidase-IN-1	Glucosidase	Metabolic Disease
β-glycosidase-IN-1 (Compound 33) is a piperidine derivative and a β-glycosidase inhibitor. β-glycosidase-IN-1 has hypoglycemic activity.

HY-W011651

Carbutamide

BZ-55
Others Metabolic Disease

Carbutamide (BZ-55) is an orally active and first-generation sulfonylurea with hypoglycemic activity.
HY-N12241

Sterebin F

Others Others

Sterebin F is a steroid isolated from the Stevia rebaudiana leaves. Sterebin F has hypoglycemic activity.

Carbutamide BZ-55	Others	Metabolic Disease
Carbutamide (BZ-55) is an orally active and first-generation sulfonylurea with hypoglycemic activity.

Sterebin F	Others	Others
Sterebin F is a steroid isolated from the Stevia rebaudiana leaves. Sterebin F has hypoglycemic activity.

HY-101048

Synthalin A sulfate	Bacterial	Infection Metabolic Disease
Synthalin A sulfate is a biguanylated diamine with antibacterial and hypoglycemic properties. Synthalin A sulfate against S. aureus with a MIC of 64 μg/mL.

HY-N7377

Butyl isobutyl phthalate	Glucosidase	Metabolic Disease
Butyl isobutyl phthalate is isolated from the rhizoid of Laminaria japonica. Butyl isobutyl phthalate is a non-competitive α-glucosidase inhibitor with an IC₅₀ value of 38 μM. Butyl isobutyl phthalate shows a hypoglycemic effect and has the potential for diabetes treatment.

HY-N4147

Eleutheroside D	Others	Metabolic Disease Inflammation/Immunology
Eleutheroside D is an active lignan isolated from the root of Eleutherococcus senticosus, has anti-inflammatory and hypoglycemic activities. Eleutheroside D is an optical isomer of Eleutheroside E (HY-N0272).

HY-121565

SaRI 59-801	Others	Endocrinology Metabolic Disease
SaRI 59-801 is an orally effective hypoglycemic compound. SaRI 59-801 decreases blood glucose in several species and to elevate plasma insulin in rats and mice.

HY-135670

Glycosidase-IN-1	Glucosidase	Metabolic Disease
Glycosidase-IN-1 (Compound 9) is a glycosidase inhibitor synthesized from D-mannose. Glycosidase-IN-1 be used to synthesize some immunosuppressive agents and β-glucosidase inhibitors. Glycosidase-IN-1 has hypoglycemic activity.

HY-N11840

Mortatarin F	Glucosidase	Metabolic Disease
Mortatarin F (Compound 1) is an inhibitor of α‑glucosidase with an IC₅₀ of 8.7 μΜ. Mortatarin F is an renylated flavonoid that can be isolated from mulberry leaves and can be used for hypoglycemic research.

HY-122943

Moracin D	Fungal Apoptosis	Cancer Infection
Moracin D is a flavonoid that can be isolated from Morus alba. Moracin D induces cell apoptosis and shows hypoglycemic, antiadipogenic, antifungal and antitumor effects. Moracin D can be used for fungal infection and breast cancer research.

HY-126067

(-)-Pinoresinol	Glucosidase Apoptosis	Inflammation/Immunology
(-)-Pinoresinol is a plant-derived tetrahydrofuran lignan that inhibits α-glucosidase and acts as a hypoglycemic agent. (-)-Pinoresinol has some anti-inflammatory effects and acts as a chemopreventive agent, inducing increased apoptosis and cell cycle G2/M arrest.

HY-128923

SKF-34288 hydrochloride 1 Publications Verification 3-Mercaptopicolinic acid hydrochloride; 3-MPA hydrochloride	PEPCK	Metabolic Disease
SKF-34288 (3-Mercaptopicolinic acid) hydrochloride is an orally active phosphoenolpyruvate carboxykinase (PEPCK) inhibitor (K_i: 2-9 μM). SKF-34288 hydrochloride is a potent hypoglycemic agent by inhibiting glucose synthesis. SKF-34288 hydrochloride also inhibits Asn metabolism and increases amino acids and amides.

HY-N0820

Catalpol Maximum Cited Publications 6 Publications Verification Catalpinoside	HBV	Cancer Infection Inflammation/Immunology Neurological Disease
Catalpol (Catalpinoside), an iridoid glycoside found in Rehmannia glutinosa. Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects.

HY-N8264

Moringin	TRP Channel	Cancer Inflammation/Immunology Neurological Disease
Moringin is a potent and selective TRPA1 ion channel natural agonist with an EC₅₀ of 3.14 μM. Moringin does not activate or activates very weakly the vanilloids somatosensory channels TRPV1, TRPV2, TRPV3 and TRPV4, and the melastatin cooling receptor TRPM8. Moringin has hypoglycemic, antimicrobial, anti-inflammatory, anticancer and neuroprotection activities.

HY-N5086

Picroside IV	HBV	Infection Metabolic Disease Inflammation/Immunology Neurological Disease
Picroside IV is an iridoid glycoside found in the underground parts of Picrorhiza scrophulariiflora. Picroside IV is a derivative of Catalpol (HY-N0820). Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects.

HY-W011220

Ciglitazone ADD-3878; U-63287	PPAR	Cancer Cardiovascular Disease
Ciglitazone is a potent and selective PPARγ agonist (EC₅₀=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells.

HY-150723

PBI-6DNJ	Glucosidase	Metabolic Disease
PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a K_i of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research.

HY-N0416

Cucurbitacin B Maximum Cited Publications 6 Publications Verification	Integrin Autophagy Apoptosis Endogenous Metabolite ROS Kinase COX	Cancer Inflammation/Immunology Neurological Disease Others
Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids and is oral active. Cucurbitacin B inhibits tumor cell growth, migration and invasion and cycle arrest, but induces cell apoptosis. Cucurbitacin B has potent anti-inflammatory, antioxidant, antiviral, hypoglycemic, hepatoprotective, neuroprotective activity.

HY-U00012

Glyhexamide

SQ 15860; Serbose; Subose
Others Metabolic Disease

Glyhexamide is an effective hypoglycemic agent in adult diabetics.
HY-B1103

Hydroxyhexamide

(±)-Hydroxyhexamid
Drug Metabolite Cardiovascular Disease

Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agents.

Glyhexamide SQ 15860; Serbose; Subose	Others	Metabolic Disease
Glyhexamide is an effective hypoglycemic agent in adult diabetics.

Hydroxyhexamide (±)-Hydroxyhexamid	Drug Metabolite	Cardiovascular Disease
Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agents.

HY-B0401

Tolbutamide 2 Publications Verification	Potassium Channel Autophagy	Metabolic Disease Cancer
Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic drug.

HY-B0401S

Tolbutamide-d9	Potassium Channel Autophagy	Metabolic Disease Cancer
Tolbutamide-d₉ is the deuterium labeled Tolbutamide. Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic agent.

HY-N9725

16-Hydroxycleroda-3,13-dien-15,16-olide 16ξ-Hydroxycleroda-3,13-dien-15,16-olide	Dipeptidyl Peptidase	Metabolic Disease
16-Hydroxycleroda-3,13-dien-15,16-olide (16ξ-Hydroxycleroda-3,13-dien-15,16-olide; HCD), a clerodane diterpene, is a potent serine protease dipeptidyl peptidase 4 (DPP-4) inhibitor. 16-Hydroxycleroda-3,13-dien-15,16-olide down-regulates LPS-induced ERK phosphorylation in myocyte but blocks GLP-1 induced PKA expression. 16-Hydroxycleroda-3,13-dien-15,16-olide exhibits hypolipidemic, hepatoprotective, hypoglycemic efficacy.

HY-B0401S1

Tolbutamide-13C	Isotope-Labeled Compounds Potassium Channel Autophagy	Metabolic Disease Cancer
Tolbutamide-¹³C is the ¹³C-labeled Tolbutamide. Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic agent.

HY-N0661

Alliin	Others	Inflammation/Immunology Cardiovascular Disease
Alliin, an orally active sulfoxide compound derived from garlic, exhibits hypoglycemic, antioxidant and anti-inflammatory activities.

HY-N0299

Stachyose hydrate	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Stachyose hydrate act as a prebiotic to enhance the growth and activity of beneficial bacteria. Stachyose hydrate exhibit a hypoglycemic effect, and improve inflammation through modulating gut microbiota.

HY-N0205

Pulchinenoside C Anemoside B4	Others	Cancer
Pulchinenoside C (Anemoside B4) is Pulsatilla koreana Nakai that have many numerous biological effects in vitro, including enhancing hypoglycemic, anti-tumor, neuroprotective and anti-angiogenic activity.

HY-B0089

Acarbose 3 Publications Verification BAY g 5421	Glucosidase	Metabolic Disease
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC₅₀=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin.

HY-B0089A

Acarbose sulfate Bay-g 5421 sulfate	Glucosidase	Metabolic Disease
Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC₅₀=11 nM). Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin.

HY-N2000

Bellidifolin	HIV	Cancer Infection Inflammation/Immunology
Bellidifolin is a xanthone isolated from the stems of Swertia punicea, with hepatoprotective, hypoglycemic, anti-oxidation, anti-inflammatory and antitumor activities. Bellidifolin also acts as a viral protein R (Vpr) inhibitor.

HY-156830

TGR5 Receptor Agonist 4	Others	Metabolic Disease
TGR5 Receptor Agonist 4 is an agonist of Bile Acid Receptor (TGR5), with EC₅₀ for hTGR5 and mTGR5 of 2 nM and 3 nM, respectively. TGR5 Receptor Agonist plays important roles in hypoglycemic and weight loss.

HY-114683

KS370G	Others	Cardiovascular Disease
KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy.

HY-148529

Midaglizole (±)-DG5128 free base; DG5128 free base	Adrenergic Receptor	Metabolic Disease
Midaglizole ((±)-DG5128 free base, DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo.

HY-N0655

D-Pinitol 3-O-Methyl-D-chiro-inositol	Influenza Virus	Infection Inflammation/Immunology Cardiovascular Disease
D-pinitol (3-O-Methyl-D-chiro-inositol) is a natural compound presented in several plants, like Pinaceae and Leguminosae plants. D-pinitol exerts hypoglycemic activity and protective effects in the cardiovascular system. D-pinitol has antiviral and larvicidal activities.

HY-N2229

Rhapontigenin 1 Publications Verification	Cytochrome P450 Fungal Bacterial	Cancer Infection Inflammation/Immunology
Rhapontigenin is a natural analog of resveratrol with anticancer, antioxidant, antifungal and antibacterial activities. Rhapontigenin is amechanism-based, potent and selective cytochrome P450 1A1 inactivator (IC₅₀ = 400 nM). Rhapontigenin exhibits 400-fold and 23-fold selectivity for P450 1A1 over P450 1A2 and P450 1B1, respectively.

HY-144035

GLP-1R agonist 4	GCGR	Cancer
GLP-1R agonist 4 is a potent agonist of GLP-1R. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 has the potential for the research of diabetes (extracted from patent WO2019239319A1, compound 96).

HY-144034

GLP-1R agonist 3	GCGR	Metabolic Disease
GLP-1R agonist 3 is a potent agonist of GLP-1R. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1).

HY-144033

GLP-1R agonist 1	GCGR	Metabolic Disease
GLP-1R agonist 1 is a potent agonist of GLP-1R. GLP-1R agonist 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 1 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 4).

HY-144717

PTP1B-IN-18	Phosphatase	Metabolic Disease
PTP1B-IN-18 is an orally active complete mixed type protein tyrosine phosphatase 1B (PTP1B) inhibitor with a K_i of 35.2 μM. PTP1B-IN-18 can be used for type 2 diabetes research.

HY-147246

Berberine ursodeoxycholate HTD1801; BUDCA	Others	Metabolic Disease
Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes.

HY-144718

PTP1B-IN-17	Phosphatase	Metabolic Disease
PTP1B-IN-17 (Compound 45), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a K_i of 30.2 μM. PTP1B-IN-17 can be used for the research of type 2 diabetes.

HY-144716

PTP1B-IN-19	Phosphatase	Metabolic Disease
PTP1B-IN-19 (Compound 43), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a K_i of 23.3 μM. PTP1B-IN-19 can be used for the research of type 2 diabetes.

HY-144713

PTP1B-IN-16	Phosphatase	Metabolic Disease
PTP1B-IN-16 (Compound 46), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a K_i of 12.6 μM. PTP1B-IN-16 can be used for the research of type 2 diabetes.

HY-P3580

Acetyl Gastric Inhibitory Peptide (human) Human N-acetyl GIP	Insulin Receptor	Endocrinology Metabolic Disease
Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity.

HY-P3580A

Acetyl Gastric Inhibitory Peptide (human) (TFA) Human N-acetyl GIP TFA	Insulin Receptor	Endocrinology Metabolic Disease
Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity.

Cat. No.	Product Name	Target	Research Area

Cat. No.	Product Name	Target	Category

Cat. No.	Product Name

hypoglycemic

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products